The All Ordinaries Index (ASX: XAO) could well enjoy an upcoming boost from two ASX All Ords stocks brokers have tipped to deliver outsized gains.
Here's how.
ASX All Ords stock on the growth path
The first stock that looks well-placed to surge higher is Intelligent Monitoring Group Ltd (ASX: IMB).
Shares in the security, monitoring and risk management services provider closed up 3.5% on Wednesday at 59 cents a share. That sees the Intelligent Monitoring share price up 13.5% in a year.
And according to the analysts at Canaccord Genuity, the ASX All Ords stock is well-placed to deliver earnings growth.
According to the broker:
In its 1Q26 result, IMB reported a 24% increase in its commercial installation pipeline to $45m, indicating strong demand from enterprise customers for security installation and upgrade work. Management noted continued growth in data centre related work as a strong feature and expects to release FY26 guidance in line with market expectations for the first time at its 10 Nov AGM.
Canaccord estimates that management will full year provide guidance for earnings before interest, taxes, depreciation and amortisation (EBITDA) of $48 million, up 25% from FY 2025 earnings.
Canaccord added:
Of note, cash on hand ended 1Q26 at $15.5m and increased to $16.2m as of 30 October despite the $4.2m acquisition payment for BNP securities during the month, reflecting a strong start to 2Q26 cash generation.
The broker said it views the ASX All Ords stock as undervalued at its current FY 2026 estimated EV/EBITDA multiple of 6 times.
Canaccord has a price target of $1.00 a share on Intelligent Monitoring. That represents more than a 69% upside from Wednesday's closing price.
Which brings us to…
Also tipped to rocket
The second ASX All Ords stock that's been tipped to rocket from current levels is Imricor Medical Systems Inc (ASX: IMR).
Shares in the human heart focused healthcare share closed down 0.7% on Wednesday, trading for $1.35 apiece. That sees the Imricor share price up an impressive 51.7% in a year.
And the analysts at Taylor Collison believe it's set to outpace those gains in the year ahead following on the recent groundbreaking heart procedure using Imricor's MRI compatible technology.
The broker noted:
Using Imricor's suite of MRI-compatible products, Amsterdam University Medical Centre (AUMC) successfully performed the world's first real-time MR-guided ischaemic ventricular tachycardia (VT) ablation in a patient with an implantable cardiac defibrillator (ICD)…
This represents a significant de-risking milestone for IMR and validates the clinical potential of MRI-guided electrophysiology (EP) procedures.
Taylor Collison added that this could help pave the way for US FDA approval in the year ahead.
Positive EU data from the VISABL-VT trial demonstrating safe and feasible transeptal crossings in VT patients both with and without ICD's is a significant catalyst for off label VT use in the US after initial FDA approval for atrial flutter (potentially late 2026)
Connecting the dots, the broker has a price target of $2.26 on the ASX All Ords stock. That represents more than a 67% upside from Wednesday's closing price.
